Your browser is no longer supported. Please, upgrade your browser.
ARVN [NASD]
Arvinas, Inc.
Index- P/E- EPS (ttm)-3.28 Insider Own2.20% Shs Outstand48.62M Perf Week6.75%
Market Cap5.25B Forward P/E- EPS next Y-3.03 Insider Trans-16.30% Shs Float42.95M Perf Month25.69%
Income-138.60M PEG- EPS next Q-0.86 Inst Own89.60% Short Float5.05% Perf Quarter47.63%
Sales21.10M P/S248.72 EPS this Y-41.40% Inst Trans0.15% Short Ratio4.17 Perf Half Y24.44%
Book/sh12.65 P/B7.94 EPS next Y-19.70% ROA-28.70% Target Price113.85 Perf Year210.93%
Cash/sh12.46 P/C8.06 EPS next 5Y- ROE-33.40% 52W Range19.68 - 108.46 Perf YTD18.22%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-7.44% Beta-
Dividend %- Quick Ratio16.50 Sales past 5Y- Gross Margin- 52W Low410.16% ATR5.39
Employees179 Current Ratio16.50 Sales Q/Q-11.30% Oper. Margin- RSI (14)65.33 Volatility6.84% 5.85%
OptionableYes Debt/Eq0.00 EPS Q/Q-49.40% Profit Margin- Rel Volume0.72 Prev Close100.40
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume520.14K Price100.40
Recom1.70 SMA2015.50% SMA5025.22% SMA20055.06% Volume0 Change0.00%
May-21-21Initiated UBS Buy $123
Apr-21-21Initiated Truist Buy $150
Mar-31-21Initiated BMO Capital Markets Outperform $101
Dec-14-20Upgrade Oppenheimer Perform → Outperform
Jun-01-20Upgrade Citigroup Neutral → Buy $45
May-12-20Initiated Oppenheimer Perform
Dec-19-19Initiated H.C. Wainwright Buy $50
Nov-25-19Initiated Guggenheim Buy $50
Oct-24-19Upgrade Goldman Neutral → Buy $23 → $38
Sep-25-19Initiated Wedbush Outperform $38
Sep-12-19Initiated BMO Capital Markets Outperform
Aug-06-19Initiated Cantor Fitzgerald Overweight $42
Jun-05-19Downgrade Citigroup Buy → Neutral $21 → $22
Apr-12-19Initiated Evercore ISI Outperform
Oct-22-18Initiated Piper Jaffray Overweight $23
Oct-22-18Initiated Goldman Neutral $17
Oct-22-18Initiated Citigroup Buy $21
Aug-01-21 10:54AM  
Jul-29-21 08:50AM  
Jul-27-21 03:02PM  
12:00PM  
Jul-26-21 03:53AM  
Jul-23-21 11:06AM  
Jul-22-21 03:21PM  
08:06AM  
07:00AM  
06:32AM  
Jul-13-21 12:32PM  
Jul-08-21 02:03AM  
Jun-07-21 05:19PM  
Jun-03-21 07:00AM  
May-21-21 04:03PM  
May-20-21 04:30PM  
May-09-21 03:10AM  
May-04-21 02:52PM  
08:45AM  
07:00AM  
Apr-22-21 05:44PM  
Apr-19-21 01:38AM  
Apr-12-21 02:28PM  
Apr-05-21 04:30PM  
Mar-10-21 04:30PM  
Mar-01-21 08:15AM  
07:59AM  
07:00AM  
Feb-18-21 12:01AM  
Feb-08-21 04:30PM  
Dec-28-20 04:30PM  
Dec-23-20 04:40PM  
Dec-16-20 01:37PM  
Dec-15-20 08:35PM  
07:48PM  
09:48AM  
09:17AM  
Dec-14-20 04:37PM  
04:06PM  
01:50PM  
09:48AM  
07:00AM  
Dec-11-20 04:15PM  
Nov-25-20 07:00AM  
Nov-16-20 09:21AM  
Nov-07-20 07:43AM  
Nov-05-20 07:00AM  
05:52AM  
Oct-14-20 07:00AM  
Oct-06-20 05:17PM  
Sep-15-20 11:42AM  
Sep-04-20 07:00AM  
Aug-07-20 07:00AM  
Aug-04-20 09:05AM  
07:00AM  
Jul-30-20 08:45AM  
Jul-27-20 12:31PM  
Jul-20-20 12:15PM  
Jun-29-20 04:30PM  
Jun-17-20 07:00AM  
Jun-15-20 09:48AM  
Jun-11-20 07:00AM  
Jun-05-20 12:00PM  
07:00AM  
May-29-20 10:28AM  
07:00AM  
May-20-20 04:30PM  
May-14-20 12:33PM  
May-13-20 05:49PM  
May-12-20 08:54AM  
May-05-20 12:00PM  
May-01-20 06:33AM  
Apr-28-20 09:37AM  
08:35AM  
07:00AM  
Apr-18-20 10:02AM  
Apr-13-20 04:54PM  
Mar-31-20 07:00AM  
06:27AM  
Mar-20-20 11:30AM  
Mar-19-20 08:56AM  
Mar-18-20 06:52AM  
Mar-16-20 08:15AM  
07:00AM  
Feb-17-20 12:00PM  
Jan-31-20 09:31AM  
Jan-29-20 06:51AM  
Jan-17-20 05:37AM  
Dec-19-19 06:27PM  
Nov-27-19 07:30AM  
Nov-26-19 08:06AM  
Nov-25-19 11:40AM  
Nov-21-19 07:30AM  
Nov-17-19 12:44PM  
Nov-06-19 09:40PM  
04:01PM  
Nov-05-19 09:00AM  
Nov-04-19 05:00PM  
Oct-31-19 11:50AM  
Oct-30-19 09:36AM  
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cassidy Sean AChief Financial OfficerJul 28Option Exercise16.0017,242275,872175,491Jul 30 08:05 PM
Cassidy Sean AChief Financial OfficerJul 28Sale100.0017,2421,724,200158,249Jul 30 08:05 PM
Peck RonaldChief Medical OfficerJun 30Option Exercise47.3820,000947,60022,754Jul 02 08:00 PM
Peck RonaldChief Medical OfficerJun 30Sale76.6920,0001,533,8002,754Jul 02 08:00 PM
Houston John GPresident and CEOJun 10Option Exercise16.0043,886702,176871,529Jun 11 08:07 PM
Houston John GPresident and CEOJun 10Sale81.4943,8863,576,263827,643Jun 11 08:07 PM
Houston John GPresident and CEOJun 09Option Exercise16.0070011,200828,343Jun 11 08:07 PM
Houston John GPresident and CEOJun 09Sale80.1570056,104827,643Jun 11 08:07 PM
Taylor IanChief Scientific OfficerApr 05Option Exercise16.0025,000400,000103,645Apr 07 06:00 PM
Taylor IanChief Scientific OfficerApr 05Sale66.8125,0001,670,14378,645Apr 07 06:00 PM
Taylor IanChief Scientific OfficerMar 02Sale77.4589469,24078,645Mar 02 09:04 PM
Cassidy Sean AChief Financial OfficerMar 02Sale77.452,221172,015158,249Mar 02 09:02 PM
Houston John GPresident and CEOMar 02Sale77.458,115628,503827,643Mar 02 09:00 PM
Taylor IanChief Scientific OfficerFeb 19Option Exercise16.006,456103,29676,854Feb 23 06:09 PM
Cassidy Sean AChief Financial OfficerFeb 17Option Exercise16.0089414,304155,678Feb 18 05:16 PM
Houston John GPresident and CEOFeb 16Option Exercise16.001,56024,960817,760Feb 18 05:26 PM
Cassidy Sean AChief Financial OfficerFeb 16Option Exercise16.0041,959671,344196,743Feb 18 05:09 PM
Houston John GPresident and CEOFeb 16Option Exercise16.0044,000704,000860,000Feb 18 05:11 PM
Peck RonaldChief Medical OfficerFeb 16Option Exercise26.5820,000531,60022,754Feb 18 05:05 PM
Houston John GPresident and CEOFeb 16Sale78.7944,0003,466,601816,200Feb 18 05:11 PM
Cassidy Sean AChief Financial OfficerFeb 16Sale78.4641,9593,292,108154,784Feb 18 05:09 PM
Peck RonaldChief Medical OfficerFeb 16Sale77.3520,0001,546,9922,754Feb 18 05:05 PM
Ratcliffe LiamDirectorDec 18Buy70.00142,8579,999,990822,857Dec 21 06:00 PM
Cassidy Sean AChief Financial OfficerNov 09Option Exercise16.003,00648,096154,784Nov 12 06:00 PM
Kennedy Edward Moore Jr.DirectorNov 09Buy23.998,333199,90942,718Nov 12 06:05 PM
Peck RonaldChief Medical OfficerAug 14Sale27.461,25634,4902,754Aug 18 07:00 PM